Vallerie Mclaughlin
Expertise in
12
conditions

Dr. Vallerie Mclaughlin

Cardiology
University Of Michigan Medical Center
1500 E Medical Center Dr, 
Ann Arbor, MI 
Offers Telehealth
Expertise in
12
conditions
University Of Michigan Medical Center
1500 E Medical Center Dr, 
Ann Arbor, MI 

Overview

Vallerie Mclaughlin is a Cardiologist in Ann Arbor, Michigan. Dr. Mclaughlin is highly rated in 12 conditions, according to our data. Her top areas of expertise are Pulmonary Hypertension, Hypertension, Systemic Sclerosis (SSc), Angioplasty, and Heart Transplant.

Her clinical research consists of co-authoring 179 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Cardiology

Licenses

Internal Medicine in MI

Hospital Affiliations

University Of Michigan Health System

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Michigan Health
  • HMO
  • INSURANCE PLAN
  • MEDICARE MAPD
Upper Peninsula Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 20 Less Insurance Carriers -

Locations

University of Michigan Medical Center
1500 E Medical Center Dr, Ann Arbor, MI 48109
Other Locations
Regents of the University of Michigan
3621 S State St, Ann Arbor, MI 48108

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk Mortality
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk Mortality
Enrollment Status: Completed
Publish Date: August 22, 2025
Intervention Type: Other, Drug
Study Drug: Sotatercept
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension
Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension
Enrollment Status: Withdrawn
Publish Date: August 14, 2024
Intervention Type: Behavioral
Study Phase: Not Applicable
Clinical Evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS™) System for Pulmonary Artery Denervation (PDN) in Patients With Pulmonary Hypertension - US
Clinical Evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS™) System for Pulmonary Artery Denervation (PDN) in Patients With Pulmonary Hypertension - US
Enrollment Status: Unknown
Publish Date: August 21, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Completed
Publish Date: April 19, 2023
Intervention Type: Drug, Other
Study Drug: Sotatercept
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Other, Biological, Drug, Diagnostic test
Study Phase: Phase 2
A Double-blinded, Placebo-controlled Pilot Study of Dimethyl Fumarate (DMF) in Pulmonary Arterial Hypertension (PAH) Associated With Systemic Sclerosis (SSc-PAH): The Effect of DMF on Clinical Disease and Biomarkers of Oxidative Stress.
A Double-blinded, Placebo-controlled Pilot Study of Dimethyl Fumarate (DMF) in Pulmonary Arterial Hypertension (PAH) Associated With Systemic Sclerosis (SSc-PAH): The Effect of DMF on Clinical Disease and Biomarkers of Oxidative Stress.
Enrollment Status: Terminated
Publish Date: March 17, 2022
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

179 Total Publications

Macitentan and phosphodiesterase-5 inhibitor alone or in combination in newly diagnosed pulmonary arterial hypertension: a pooled analysis.
Macitentan and phosphodiesterase-5 inhibitor alone or in combination in newly diagnosed pulmonary arterial hypertension: a pooled analysis.
Journal: JHLT open
Published: January 22, 2026
Similar Doctors
Expertise in
30
conditions
Dr. Sara Saberi
Cardiology
Expertise in
30
conditions
Dr. Sara Saberi
Cardiology

Office

1425 E Ann St Spc 5856, 
Ann Arbor, MI 
 (1.1 miles away)
888-287-1082
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sara Saberi is a Cardiologist in Ann Arbor, Michigan. Dr. Saberi is highly rated in 30 conditions, according to our data. Her top areas of expertise are Hypertrophic Cardiomyopathy (HCM), Cardiomyopathy, Familial Hypertrophic Cardiomyopathy, Cardiac Ablation, and Pacemaker Implantation.

Kim Eagle
Expertise in
40
conditions
Dr. Kim Eagle
Cardiology
Expertise in
40
conditions
Dr. Kim Eagle
Cardiology

Office

4029 Maria St Ste A, 
Ann Arbor, MI 
 (3.4 miles away)
888-287-1082
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kim Eagle is a Cardiologist in Ann Arbor, Michigan. Dr. Eagle is highly rated in 40 conditions, according to our data. His top areas of expertise are Aortic Dissection, Marfan Syndrome, Thoracic Aortic Aneurysm, Cardiac Ablation, and Percutaneous Coronary Intervention (PCI).

Expertise in
23
conditions
Dr. Stanley Chetcuti
Cardiology
Expertise in
23
conditions
Dr. Stanley Chetcuti
Cardiology

University Of Michigan Medical Center

1500 E Medical Center Dr, 
Ann Arbor, MI 
 (0.2 miles away)
888-287-1082
Languages Spoken:
English
See accepted insurances

Stanley Chetcuti is a Cardiologist in Ann Arbor, Michigan. Dr. Chetcuti is highly rated in 23 conditions, according to our data. His top areas of expertise are Aortic Valve Stenosis, Aortic Regurgitation, Mitral Valve Regurgitation, Transcatheter Aortic Valve Replacement (TAVR), and Aortic Valve Replacement.

Frequently Asked Questions about Dr. Vallerie Mclaughlin

How do I make an appointment with Dr. Vallerie Mclaughlin?

You can book an appointment with Dr. Vallerie Mclaughlin by calling their office at 888-287-1082. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Vallerie Mclaughlin a top-rated expert for Pulmonary Hypertension?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Vallerie Mclaughlin is classified as an Elite expert for Pulmonary Hypertension, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Vallerie Mclaughlin specialize in?

While Dr. Vallerie Mclaughlin is a Cardiology, they have specific expertise in Pulmonary Hypertension, Hypertension, and Systemic Sclerosis (SSc). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Cardiology.

Does Dr. Vallerie Mclaughlin participate in research or clinical trials?

Yes. Dr. Vallerie Mclaughlin has published 179 articles and abstracts on conditions like Pulmonary Hypertension. You can view a list of Dr. Vallerie Mclaughlin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Vallerie Mclaughlin accept my insurance?

Dr. Vallerie Mclaughlin accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 888-287-1082 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mclaughlin's expertise for a condition
ConditionClose
View All 49 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile